Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TBN +2.1%
Other news:
- AKAM +20.0% (Signed an $11.6 billion, seven-year Anthropic cloud deal, with potential expansion of up to $9 billion.)
- FTHM +13.5% (Proposes combining its national residential brokerage and title business with Neighborhood Intelligence's digital-asset interests.)
- PRME +11.1% (Received FDA clearance to begin U.S. clinical trials of PM647 for Alpha-1 Antitrypsin Deficiency.)
- PPLI +8.1% (MGM Resorts is reportedly considering a bid for People Incorporated.)
- AESI +6.9% (Entered agreements to purchase $340.5 million in balance-of-plant equipment and $273 million in power-generation equipment and services.)
- WTTR +5.4% (Agreed to acquire Pilot Water Solutions for $700 million, adding substantial EBITDA and targeting $10-$15 million in annual synergies.)
- RGNX +3.9% (Reported three-year Phase II sura-vec data showing 60% achieved greater than two-step DRSS improvement without additional treatment.)
- FATE +3.9% (Received a $15 million CIRM grant supporting the potentially registrational Phase 2 RECLAIM-LN trial of FT819.)
- NKTR +3.8% (Won a $90 million jury award against Eli Lilly for breaching an implied covenant in their license agreement.)
- OCGN +3.0% (Received provisional Bahamas approval and priority designation for OCU400, enabling expanded-access treatment progress for retinitis pigmentosa.)
- NXH +2.4% (Proposed restructuring would combine Fathom's brokerage and title businesses with interests in tZERO, Medici and GrainChain.)
- FRMI +2.4% (Selected CBRE as exclusive operations and maintenance provider for its first data center under a five-year agreement.)
- STAA +2.2% (Authorized a $50 million share repurchase program expected to run over the next 12 months.)
- ETN +2.0% (Agreed to acquire COL Group for €810 million, expanding EMEA power distribution capacity.)
- JBL +2.0% (Secured a build request authorizing approximately $1.7 billion in memory-component purchases under its Akamai services agreement.)
- CCCC +2.0% (Reported biomarker activity and safety clearance for 75-µg cemsidomide combined with elranatamab in relapsed/refractory multiple myeloma.)
- WALD +1.9% (Filed to voluntarily delist shares and warrants from Nasdaq, with the last trading day expected around Oct. 2.)
- IQ +1.9% (Unveils over 350 titles for 2026-2027 and expands its AI content strategy.)
- ALMR +1.9% (A Lancet Neurology study used Alamar's NULISAseq panel to evaluate Alzheimer's treatment responses.)